The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens

M. A. Dimopoulos, E. Kastritis, S. Delimpassi, A. Zomas, M. C. Kyrtsonis, K. Zervas
2008 Haematologica  
not need an alloSCT for cure after relapse. Results of the ongoing International BFM Study Group Pediatric Relapsed AML protocol, will contribute to this discussion in the near future. The Dutch and literature data suggest that randomized studies of the role of alloSCT in subgroups of relapsed AML are required. Meanwhile, experimental allogeneic SCT procedures, such as haplo-identical and mismatched unrelated donor SCT, should be carefully balanced against the chance of cure by chemotherapy
more » ... by chemotherapy only in patients in good quality second complete remission of AML.
doi:10.3324/haematol.12846 pmid:18641029 fatcat:rmtwbg26ovbyxlt35d5lxgvg6i